- Published on Sunday, 23 September 2012 03:58
- Written by Small Sector
TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting. Tonix Pharmaceuticals Holding Corp is a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes. Today they announced the on-line publication of the abstract of preclinical and human pharmacokinetic data related to the Company's fibromyalgia and post-traumatic stress disorder programs. It will present theses findings at the 2012 American Co llege of Rheumatology held from November 10-14, at the Walter E. Washington Convention Center in Washington, D.C.
Fibromyalgia is a common and complex central nervous system condition characterized by chronic diffuse musculoskeletal pain, increased pain sensitivity at multiple tender points, fatigue, abnormal pain processing, and disturbed sleep. This often features psychological stress. Despite the fact that most patients suffer from poor sleep, there are no medications indicated for FM that work by improving sleep quality. Research has shown that the restorative sleep of patients is disrupted by alarm signals called CAP A2 and A3. In a Phase 2a trial, TONIX demonstrated that bedtime administration of very low dose cyclobenzaprine improves core FM symptoms including pain, tenderness, fatigue, and depression, and also demonstrated that improvements in key symptoms correlate with increased nights of restorative sleep.
TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX's lead product is designed to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments. Its most advanced product candidate, TNX-102 SL for FM and post-traumatic stress disorder, is a novel dosage formulation of cyclobenzaprine.